Lipid Metabolism, Inborn Errors
Errors in the metabolism of LIPIDS resulting from inborn genetic MUTATIONS that are heritable.
Subtype terms (15)
More specific conditions that are subtypes of Lipid Metabolism, Inborn Errors in the MeSH hierarchy.
- Barth Syndrome
2 drugs approved
- Hyperlipidemia, Familial Combined
5 drugs approved
- Hyperlipoproteinemia Type I
12 drugs (7 approved, 5 experimental)
- Hyperlipoproteinemia Type II
43 drugs (21 approved, 22 experimental)
- Hyperlipoproteinemia Type III
7 drugs (6 approved, 1 experimental)
- Hyperlipoproteinemia Type IV
7 drugs (4 approved, 3 experimental)
- Hyperlipoproteinemia Type V
4 drugs (1 approved, 3 experimental)
- Hypobetalipoproteinemia, Familial, Apolipoprotein B
- Hypolipoproteinemias
2 drugs approved
- Lipidoses
1 drug approved
- Lipodystrophy, Congenital Generalized
3 drugs (1 approved, 2 experimental)
- Lipodystrophy, Familial Partial
7 drugs (3 approved, 4 experimental)
- Shwachman-Diamond Syndrome
16 drugs (13 approved, 3 experimental)
- Smith-Lemli-Opitz Syndrome
6 drugs (3 approved, 3 experimental)
- Xanthomatosis, Cerebrotendinous
2 drugs approved
Drugs by status
Phase 3 trials (3)
Phase 1 trials (1)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (1)
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (10)